NOVAVAX INC (NVAX) Total liabilities 2016–2025
NOVAVAX INC (NVAX) total liabilities at each fiscal year-end, per SEC filings.
$1.3BFY2025 · since FY2016: $399.8M → $1.3B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $1.3B | -40.3% |
| FY2024 | $2.2B | -13.1% |
| FY2023 | $2.5B | -13.1% |
| FY2022 | $2.9B | -1.2% |
| FY2021 | $2.9B | +206.6% |
| FY2020 | $955.3M | +166.1% |
| FY2019 | $359.0M | -4.5% |
| FY2018 | $375.9M | -7.0% |
| FY2017 | $404.2M | +1.1% |
| FY2016 | $399.8M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More NVAX financial trends
NVAX RevenueNVAX Net incomeNVAX Net marginNVAX Gross profitNVAX Gross marginNVAX Operating incomeNVAX Operating marginNVAX Operating cash flowNVAX Free cash flowNVAX Capital expendituresNVAX Return on equityNVAX Stock buybacksNVAX Dividends paidNVAX Total assetsNVAX Shareholders’ equityNVAX overview →